The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
C-reactive protein (CRP) as a predictive marker for survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first line pembrolizumab monotherapy.
 
Yuji Shibata
No Relationships to Disclose
 
Tadasuke Shimokawaji
Honoraria - AstraZeneca; Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
 
Tetsuro Kondo
No Relationships to Disclose
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; Roche; Sumitomo Dainippon; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Haruhiro Saito
No Relationships to Disclose
 
Kouzo Yamada
No Relationships to Disclose